OBJECTIVE
METHODS
RESULTS
CONCLUSION
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to UrologyReferences
- Best practice in the treatment of nonmuscle invasive bladder cancer.Ther Adv Urol. 2012; 4: 13-32
Surveillance EaERP. Cancer Stat Facts: Bladder Cancer. Available at: https://seer.cancer.gov/statfacts/html/urinb.html. Accessed May 10, 2019.
- Diagnosis and management of superficial bladder cancer.Curr Probl Cancer. 2001; 25: 219-278
- Non-muscle invasive bladder cancer risk stratification.Indian J Urol. 2015; 31: 289-296
- Diagnosis and treatment of non-muscle invasive bladder cancer: AUA/SUO guideline.J Urol. 2016; 196: 1021-1029
- EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2016.Eur Urol. 2017; 71: 447-461
- NCCN Clinical Practice Guidelines in Oncology: Bladder Cancer. V1.2019.2018
- Adjuvant intravesical bacillus calmette-guerin therapy and survival among elderly patients with non-muscle-invasive bladder cancer.J Oncol Pract. 2013; 9: 92-98
- SEER-Medicare: Brief Description of the SEER-Medicare Database.2018 (Available at:) (Accessed May 10, 2019)
- A novel approach to improve health status measurement in observational claims-based studies of cancer treatment and outcomes.J Geriatr Oncol. 2013; 4: 157-165
- Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases.J Clin Epidemiol. 1992; 45: 613-619
- Development of a comorbidity index using physician claims data.J Clin Epidemiol. 2000; 53: 1258-1267
- SEER-Medicare: Selecting the Appropriate Comorbidity SAS Macro.2019 (Available at:) (Accessed May 10, 2019)
- National Cancer Institute Division of Cancer Control and Population Sciences. Healthcare Delivery Research Program: Comorbidity SAS Macro (2014 version).2018 (Available at:) (Accessed May 10, 2019)
Chuo CY, Richards KA, Zivkovic M, et al. Validation of an algorithm in administrative claims to identify adequate intravesical Bacillus Calmette-Guérin therapy in elderly patients with non–muscle-invasive bladder cancer. Poster presented at: 33rd International Conference on Pharmacoepidemiology & Therapeutic Risk Management (ICPE 2017). August 26-30, 2017; Montreal, QC, Canada.
United States Department of Health and Human Services. Food and Drug Administration. BCG-unresponsive nonmuscle invasive bladder cancer: developing drugs and biologics for treatment. Guidance for industry. 2018. Available at: https://www.fda.gov/media/101468/download. Accessed May 15, 2020.
- Development of systemic and topical drugs to treat non-muscle invasive bladder cancer.Bl Cancer. 2015; 1: 133-136
- Definitions, end points, and clinical trial designs for non–muscle-invasive bladder cancer: recommendations from the International Bladder Cancer Group.J Clin Oncol. 2016; 34: 1935-1944
- Challenges of guarantee-time bias.J Clin Oncol. 2013; 31: 2963-2969
- Predictors of intravesical therapy for nonmuscle invasive bladder cancer: results from the surveillance, epidemiology and end results program 2003 patterns of care project.J Urol. 2008; 180 (discussion 524): 520-524
- Patterns of care for early stage bladder cancer.Cancer. 2010; 116: 2604-2611
- Manufacturing and the market: rationalizing the shortage of Bacillus Calmette-Guerin.Eur Urol Focus. 2018; 4: 481-484
- Expert consensus document: consensus statement on best practice management regarding the use of intravesical immunotherapy with BCG for bladder cancer.Nat Rev Urol. 2015; 12: 225-235
- Provider treatment intensity and outcomes for patients with early-stage bladder cancer.J Natl Cancer Inst. 2009; 101: 571-580
- Understanding the variation in treatment intensity among patients with early stage bladder cancer.Cancer. 2010; 116: 3587-3594
- Quality of care in patients with bladder cancer: a case report?.Cancer. 2012; 118: 1412-1421
Article info
Publication history
Footnotes
Financial disclosures: Kyle Richards certifies that all conflicts of interest, including specific financial interests, relationships, and affiliations relevant to the subject matter or materials discussed in the manuscript (eg, employment/affiliation, grants or funding, consultancies, honoraria, stock ownership or options, expert testimony, royalties, or patents filed, received, or pending) are the following: All authors report funding of editorial support from F. Hoffmann-La Roche, Ltd. Kyle A. Richards has nothing to disclose. Sandip Prasad received personal fees (advisory board) from UroGen outside of the submitted work. Shih-Wen Lin, Ching-Yi Chuo, Christina Derleth, and Sarika Ogale are or were employed by Genentech-Roche during the study and own or owned Roche stock. Christina Derleth is currently employed by Seattle Genetics and owns stock in the company. Jingbo Yi and Marko Zivkovic are or were employed by Genesis Research during the study. Guarionex J. Decastro received research funding from Karl Storz Endoscopy-America outside the submitted work, educational monies from Coloplast Corp outside the submitted work, and food/beverage monies from Karl Storz Endoscopy-America and Astellas Pharma US outside the submitted work. Gary D. Steinberg received personal fees (scientific advisor role) from Merck, Genentech-Roche, Bristol-Myers Squibb, Ferring Pharmaceuticals, Janssen, AstraZeneca, Cold Genesys, UroGen, Photocure, Pfizer, Epivax Oncology and SesenBio outside of the submitted work.
Funding/support and role of the sponsor: F. Hoffmann-La Roche, Ltd. sponsored the study and was involved in the design and conduct of the study; management, analysis and interpretation of the data; and preparation, review and approval of the manuscript.
Authors’ contributions: All authors had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis; Study concept and design: Ching-Yi Chuo, Christina Derleth, Gary Steinberg, Guarionex J. Decastro, Kyle Richards, Sarika Ogale, Shih-Wen Lin; Acquisition of data: Not applicable; Analysis and interpretation of data: Ching-Yi Chuo, Christina Derleth, Gary Steinberg, Kyle Richards, Jingbo Yi, Marko Zivkovic, Sandip Prasad, Sarika Ogale, Shih-Wen Lin; Drafting of the manuscript: Kyle Richards, Shih-Wen Lin; Critical revision of the manuscript for important intellectual content: All authors; Statistical analysis: Ching-Yi Chuo, Jingbo Yi, Marko Zivkovic; Obtaining funding: N.A.; Administrative, technical, or material support: N.A.; Supervision: Kyle Richards, Shih-Wen Lin; Other: N.A.
